Page 107 - Read Online

Remley et al. Cancer Drug Resist 2023;6:748-67 https://dx.doi.org/10.20517/cdr.2023.63 Page 762

Authors’ contributions
Made substantial contributions to the conception, outline, and writing: Remley VA, Dimastromatteo J
Performed critical review/editing for scientific accuracy: Linden J, Bauer TW

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Drs. Dimastromatteo and Linden are members of Adovate, a for-profit company dedicated to improving
patient health using a new generation of adenosine analogs.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why
does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book 2019;39:147-64. DOI PubMed
2. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol
2005;167:627-35. DOI PubMed PMC
3. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug
Discov 2019;18:197-218. DOI PubMed
4. Rubin SJS, Sojwal RS, Gubatan J, Rogalla S. The tumor immune microenvironment in pancreatic ductal adenocarcinoma: neither hot
nor cold. Cancers 2022;14:4236. DOI PubMed PMC
5. Johnson A, Townsend M, O’Neill K. Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid
tumors. Cells 2022;11:3626. DOI PubMed PMC
6. Nallanthighal S, Heiserman JP, Cheon DJ. The role of the extracellular matrix in cancer stemness. Front Cell Dev Biol 2019;7:86.
DOI PubMed PMC
7. Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune
cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007;56:1687-
700. DOI PubMed
8. Huang X, Li Y, Fu M, Xin HB. Polarizing macrophages in vitro. In: Rousselet G, editor. Macrophages. New York, NY: Springer
New York; 2018. p. 119-26. Available from: http://link.springer.com/10.1007/978-1-4939-7837-3_12. [Last accessed on 18 Oct
2023].
9. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related
inflammation. J Leukoc Biol 2009;86:1065-73. DOI
10. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51. DOI PubMed PMC
11. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res
2012;72:2162-71. DOI PubMed PMC
12. Choueiry F, Torok M, Shakya R, et al. CD200 promotes immunosuppression in the pancreatic tumor microenvironment. J
Immunother Cancer 2020;8:e000189. DOI PubMed PMC
13. Shi R, Tang YQ, Miao H. Metabolism in tumor microenvironment: implications for cancer immunotherapy. MedComm 2020;1:47-
68. DOI PubMed PMC
14. Hatfield SM, Kjaergaard J, Lukashev D, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci
Transl Med 2015;7:277ra30. DOI PubMed PMC
15. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on